The Influence of Obesity on Small Bowel Capsule Endoscopy
Table 2
Background factors and intestinal transit times with and without obesity.
Obesity (O) () (%)
Nonobesity (NO) () (%)
value
Males
30 (55.6)
153 (53.5)
0.8819
Age (yrs)
55.5 (41–63.8)
47 (29.8–69)
0.1947
Preparation (15 mg mosapride)
44 (81.5)
239 (83.6)
0.6935
Height (cm)
163.3 (154.8–170.3)
163 (155.5–169.6)
0.6952
Weight (kg)
73.5 (67–80)
53.6 (41.9–60)
<0.0001
BMI (kg/m2)
27 (25.9–28.5)
20.4 (18.4–22.4)
<0.0001
Comorbidities
Hypertension
18 (33.3)
83 (29)
0.5200
Heart disease
12 (22.2)
51 (17.8)
0.4478
Diabetes mellitus
10 (18.5)
35 (12.2)
0.2712
Liver cirrhosis
5 (9.3)
12 (4.2)
0.1628
Hemodialysis
4 (7.4)
10 (3.5)
0.2511
IBS-D
2 (3.7)
14 (4.9)
1.0000
Crohn’s disease
6 (11.1)
52 (18.2)
0.2410
Constipation
6 (11.1)
30 (10.5)
0.8132
Laboratory data
Hemoglobin (g/dL)
11.8 (9.3–14.2)
12 (9.5–13.7)
0.9464
Platelet (×1044/μL)
23.2 (19.2–30.7)
22.9 (18.2–29.2)
0.5971
Albumin (g/dL)
4.1 (3.6–4.4)
3.9 (3.3–4.4)
0.2588
BUN (mg/dL)
15.3 (11.7–32.3)
13.2 (10–19.7)
0.0895
Cr (mg/dL)
0.81 (0.66–1.08)
0.79 (0.65–0.97)
0.4815
Intestinal transit time
ETT (sec)
3 (2–5)
3 (2–8)
0.4057
GTT (min)
12.5 (7.8–33.5)
15 (8–32)
0.6968
SBTT (min)
177 (122.8–242.9)
227 (162.8–320)
0.0026
SBCE findings
Erosion, ulcer
19 (35.2)
104 (36.4)
1.0000
Active bleeding
4 (7.4)
24 (8.4)
1.0000
Tumor
2 (3.7)
22 (7.7)
0.3943
Inpatient examination
20 (37)
116 (40.6)
0.6531
Urgent examination
5 (9.3)
17 (5.9)
0.3664
The data are median (interquartile range) or number (%) of patients. BMI: body mass index; BUN: blood urea nitrogen; Cr: creatinine; IBS-D: diarrhea-predominant irritable bowel syndrome; ETT: esophagus transit time; GTT: gastric transit time; SBTT: small bowel transit time.
